X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir.
Klei, H.E., Kish, K., Lin, P.F., Guo, Q., Friborg, J., Rose, R.E., Zhang, Y., Goldfarb, V., Langley, D.R., Wittekind, M., Sheriff, S.(2007) J.Virol. 81: 9525-9535
- PubMed: 17537865 
- DOI: 10.1128/JVI.02503-05
- Primary Citation of Related Structures:  
- PubMed Abstract: 
Atazanavir, which is marketed as REYATAZ, is the first human immunodeficiency virus type 1 (HIV-1) protease inhibitor approved for once-daily administration. As previously reported, atazanavir offers improved inhibitory profiles against several commo ...